

## 2012 (47)

Audet-Walsh Étienne, Bellemare Judith, Lacombe Louis, Fradet Yves, Fradet Vincent, Douville Pierre, Guillemette Chantal, Lévesque Éric. The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy. *European Urology*. 2012 July; 62 88-96

Bender JL, Wiljer D, Matthew A, Canil CM, Legere L, Loblaw A, Jewett MAS. Fostering partnerships in survivorship care: report of the 2011 Canadian genitourinary cancers survivorship conference. *Journal of Cancer Survivorship-Research and Practice*. 2012 Sep; 6 (3) 296-304

Bismar TA, Dolph M, Teng LH, Liu SH, Donnelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. *European Journal of Cancer*. 2012 Mar; 48 (4) 538-546

Bismar TA, Yoshimoto M, Duan QL, Liu SH, Sircar K, Squire JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. *Histopathology*. 2012 Mar; 60 (4) 645-652

Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. *BMC Cancer*. 2012 Nov; 12 543

Choucair KA, Guerard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. *Translational Oncology*. 2012 Dec; 5 (6) 453-460

Collins CC, Volik SV, Lapuk AV, Wang YW, Gout PW, Wu CX, Xue H, Cheng HW, Haegert A, Bell RH, Brahmabhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, Bertino JR, Lubin M, Wang YZ. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. *Molecular Cancer Therapeutics*. 2012 Mar; 11 (3) 775-783

Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. *Prostate Cancer and Prostatic Diseases*. 2012 Dec; 15 (4) 346-352

Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R. Role of proprotein convertases in prostate cancer progression. *Neoplasia*. 2012 Nov; 14 (11) 1032-U165

Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD. The emerging role of histone lysine demethylases in prostate cancer. *Molecular Cancer*. 2012 Aug; 11 52

Das GK, Johnson NJJ, Cramen J, Blasiak B, Latta P, Tomanek B, van Veggel FCJM. NaDyF4 Nanoparticles as T-2 Contrast Agents for Ultrahigh Field Magnetic Resonance Imaging. *Journal of Physical Chemistry Letters*. 2012 Feb; 3 (4) 524-529

Daze KD, Ma MCF, Pineux F, Hof F. Synthesis of New Trisulfonated Calix[4]arenes Functionalized at the Upper Rim and Their Complexation with the Trimethyllysine Epigenetic Mark. *Organic Letters*. 2012 Mar; 14 (6) 1512-1515

Daze KD, Pinter T, Beshara CS, Ibraheem A, Minaker SA, Ma MCF, Courtemanche RJM, Campbell RE, Hof F. Supramolecular hosts that recognize methyllysines and disrupt the interaction between a modified histone tail and its epigenetic reader protein. *Chemical Science*. 2012 3 (9) 2695-2699

Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, John RDO, Groskopf J, Joshua AM. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. *BJU International*. 2012 Sep; 110 (6) 840-845

Draker R, Ng MK, Sarcinella E, Ignatchenko V, Kislinger T, Cheung P. A combination of H2A.Z and H4 acetylation recruit Brd2 to chromatin during transcriptional activation. *PLoS Genetics*. 2012 Nov; 8 e1003047

Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. *Cancer Letters*. 2012 Feb; 315 (1) 38-47

Fang YQ, Qiu QY, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ. Combi-targeting mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. *Prostate*. 2012 Sep; 72 (12) 1273-1285

Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN Deletion in Prostate Cancer Cells Does Not Associate With Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. *Clinical Cancer Research*. 2012 Feb; 18 (4) 1015-1027

Girgis AH, Bui A, White NM, Yousef GM. Integrated Genomic Characterization of the Kallikrein Gene Locus in Cancer. *Anticancer Research*. 2012 Mar; 32 (3) 957-963

Gottlieb Bruce, Beitel Lenore K, Nadarajah Abbasha, Paliouras Miltiadis, Trifiro Mark. The Androgen Receptor Gene Mutations Database: 2012 Update. *Human Mutation*. 2012 May; 33 887-894

Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. *Oncogene*. 2012 Sep; 31 (37) 4164-4170

Inder KL, Zheng YZ, Davis MJ, Moon H, Loo D, Nguyen H, Clements JA, Parton RG, Foster LJ, Hill MM. Expression of PTRF in PC-3 Cells modulates cholesterol Dynamics and the Actin Cytoskeleton Impacting Secretion Pathways. *Molecular and Cellular Proteomics*. 2012 Feb; 11 M111.012245

Klotz L. Active surveillance: the Canadian experience. *Current Opinion in Urology*. 2012 May; 22 (3) 222-230

Lapuk AV, Wu CX, Wyatt AW, McPherson A, McConeghy BJ, Brahmabhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang YZ, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao YJ, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. *Journal of Pathology*. 2012 July; 227 (3) 286-297

Lee JB, Zhang KX, Tam YYC, Tam YK, Belliveau NM, Sung VYC, Lin PJC, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. *International Journal of Cancer*. 2012 Sep; 131 (5) E781-E790

Levesque C, Fugere M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prah A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. *Journal of Medicinal Chemistry*. 2012 Dec; 55 (23) 10501-10511

Liu Tracy W, MacDonald Thomas D, Shi Jiyun, Wilson Brian C, Zheng Gang. Intrinsically copper-64-labeled organic nanoparticles as radiotracers. *Angewandte Chemie*. 2012 Dec; 51 13128-13131

Lowes Lori E, Hedley Benjamin D, Keeney Mike, Allan Alison L. User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch® system. *Cytometry Part A*. 2012 Nov; 81 983-995

Lu Chen, McFarland Mark S, Nesbitt Rae-Lynn, Williams Andrew K, Chan Susanne, Gomez-Lemus Jose, Autran-Gomez Anna Maria, Al-Zahrani Ali, Chin Joseph L, Izawa Jonathan I, Luyt Leonard G, Lewis John D. Ghrelin Receptor as a Novel Imaging Target for Prostatic Neoplasms. *Prostate*. 2012 Jun; 72 825-833

Madeira JM, Beloukhina N, Boudreau K, Boettcher TA, Gurley L, Walker DG, McNeil WS, Klegeris A. Cobalt(II) beta-ketoamino complexes as novel inhibitors of neuroinflammation. *European Journal of Pharmacology*. 2012 Feb; 676 81-88

Margel D, Yap SA, Lawrentschuk N, Klotz L, Haider M, Hersey K, Finelli A, Zlotta A, Trachtenberg J, Fleshner N. Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study. *Journal of Urology*. 2012 Apr; 187 (4) 1247-1252

Metser U, Goldstein MA, Chawla TP, Fleshner NE, Jacks LM, O'Malley ME. Detection of Urothelial Tumors: Comparison of Urothelial Phase with Excretory Phase CT Urography-A Prospective Study. *Radiology*. 2012 July; 264 (1) 110-118

Petersen LF, Brockton NT, Bakkar A, Liu SH, Wen J, Weljie AM, Bismar TA. Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. *BJU International*. 2012 Mar; 109 (5) 788-795

Petraki C, Dubinski W, Scorilas A, Saleh C, Pasic MD, Komborozos V, Khalil B, Gabriel MY, Streutker C,

Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. *Pathology Research and Practice* . 2012 208 (2) 104-108

Petraki C, Youssef YM, Dubinski W, Lichner Z, Scorilas A, Pasic MD, Komborozos V, Khalil B, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. *Tumor Biology*. 2012 Aug; 33 (4) 1209-1214

Pollak Michael N. Investigating metformin for cancer prevention and treatment: the end of the beginning. *Cancer Discovery*. 2012 Sep; 2 778-790

Storozhuk Y, Sanli T, Hopmans SN, Schultz C, Farrell T, Cutz JC, Steinberg GR, Wright J, Singh G, Tsakiridis T. Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts. *Radiation Oncology*. 2012 May; 7 71

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. *Prostate*. 2012 Jun; 72 (8) 875-885

Twiddy Alexis L, Cox Michael E, Wasan Kishor M. Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. *Prostate*. 2012 Jun; 72 955-965

Venkateswaran Seetha, Margel David, Yap Stanley, Hersey Karen, Yip Paul, Fleshner Neil Eric. Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate. *Canadian Urological Association Journal*. 2012 Jun; 6 183-186

Venugopal N, McCurdy B, Al Mehairi S, Alamri A, Sandhu G, Sivalingam S, Drachenberg D, Ryner L. Short echo time in vivo prostate 1H-MRSI. *Magnetic Resonance Imaging*. 2012 Feb; 30 (2) 195-204

Venugopal N, McCurdy B, Hovdebo J, Al Mehairi S, Alamri A, Sandhu GS, Sivalingam S, Drachenberg D, Ryner L. Automatic conformal prescription of very selective saturation bands for in vivo 1H-MRSI of the prostate. *NMR in Biomedicine*. 2012 Apr; 25 (4) 643-653

Vesprini D, Catton C, Jacks L, Lockwood G, Rosewall T, Bayley A, Chung P, Gospodarowicz M, Menard C, Milosevic M, Nichol A, Skala M, Warde P, Bristow RG. Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*. 2012 Jun; 83 (2) 608-616

Wafa LA, Cheng HL, Plaa N, Ghaidi F, Fukumoto T, Fazli L, Gleave ME, Cox ME, Rennie PS. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. *International Journal of Cancer*. 2012 Jun; 130 (12) 2835-2844

Wu CX, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmabhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F,

Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Jones SJM, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Sahinalp SC, Gleave ME, Volik SV, Collins CC. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. *Journal of Pathology*. 2012 May; 227 (1) 53-61

Wu CX, Wyatt AW, McPherson A, Lin D, McConeghy BJ, Mo F, Shukin R, Lapuk AV, Jones SJM, Zhao YJ, Marra MA, Gleave ME, Volik SV, Wang YZ, Sahinalp SC, Collins CC. Poly-gene fusion transcripts and chromothripsis in prostate cancer. *Genes Chromosomes and Cancer*. 2012 Dec; 51 (12) 1144-1153

Xie YY, Yan J, Cutz JC, Rybak AP, He LZ, Wei FX, Kapoor A, Schmidt VA, Tao LJ, Tang DM. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. *Biochimica et Biophysica acta - Molecular Basis of Disease*. 2012 Jun; 1822 (6) 875-884